Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Christopher H. Crane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5143-2784; OpenAlex author ID A5016694714, A5112812048. Sources: ClinicalTrials.gov.

Their work

Papers
67 (first author 2, last author 10)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
213
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 3 papers · 2012: 7 papers, 1 trial · 2013: 1 paper · 2014: 6 papers · 2015: 4 papers · 2016: 8 papers · 2017: 5 papers · 2018: 4 papers · 2019: 2 papers · 2020: 4 papers · 2021: 7 papers · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 67

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Last author DOI 10.1001/jamasurg.2026.2988↗
  2. Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0772↗
  3. Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1762867↗
  4. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Last author DOI 10.1001/jamaoncol.2025.0460↗
  5. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  6. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  7. Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hyp… Co-author DOI 10.3390/cancers17152596↗
  8. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  9. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  10. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2023.03.036↗
  11. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  12. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.04.044↗
  13. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  14. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Last author DOI 10.1016/j.phro.2022.10.003↗
  15. CT and cone-beam CT of ablative radiation therapy for pancreatic cancer with expert organ-at-risk contours. Co-author DOI 10.1038/s41597-022-01758-9↗
  16. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  17. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Last author DOI 10.1001/jamaoncol.2021.0057↗
  18. Deep-learning-based image registration and automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of pancreatic canc… Co-author DOI 10.1002/mp.14906↗
  19. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Last author DOI 10.1016/j.ijrobp.2020.08.042↗
  20. Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. Last author DOI 10.1016/j.soc.2021.06.009↗
  21. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  22. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  23. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Co-author DOI 10.3389/fonc.2021.628155↗
  24. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international syste… Co-author DOI 10.1002/cncr.32756↗
  25. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Co-author DOI 10.1016/j.prro.2020.01.012↗
  26. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  27. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Last author DOI 10.1634/theoncologist.2019-0562↗
  28. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Last author DOI 10.1186/s13014-019-1309-x↗
  29. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  30. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG … Co-author DOI 10.1002/cncr.31058↗
  31. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therap… Co-author DOI 10.1002/cncr.31251↗
  32. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  33. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  34. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  35. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Co-author DOI 10.1016/j.ijrobp.2016.10.046↗
  36. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Co-author DOI 10.1016/j.prro.2016.10.006↗
  37. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1342863↗
  38. Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). Co-author DOI 10.1097/ppo.0000000000000292↗
  39. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. First author DOI 10.1002/cncr.30117↗
  40. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  41. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Co-author DOI 10.1016/j.ijrobp.2015.10.062↗
  42. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolida… Last author DOI 10.1016/j.ijrobp.2015.12.003↗
  43. Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1093/jrr/rrw016↗
  44. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.1412↗
  45. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5561↗
  46. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0156910↗
  47. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1245/s10434-014-4192-6↗
  48. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Co-author DOI 10.1245/s10434-015-4854-z↗
  49. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Co-author DOI 10.3109/0284186x.2014.1000466↗
  50. Improving Long-Term Survival in Patients With Locally Advanced Pancreatic Cancer via the Delivery of Definitive Radiotherapy Doses. Co-author PMID 26281840↗

Trials 4

  1. Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advan… Principal investigator NCT01298401↗
  2. Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients Principal investigator NCT00338039↗
  3. Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT00047710↗
  4. Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT01017822↗

Closest collaborators

The 25 strongest of 213 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 17 shared papers, 2016–2026 · strength 2.55
  2. Marsha Reyngold · 16 shared papers, 2017–2026 · strength 2.50
  3. Carla Hajj · 9 shared papers, 2017–2026 · strength 1.37
  4. Matthew H. G. Katz · 28 shared papers, 2011–2022 · strength 1.36
  5. Anna M. Varghese · 8 shared papers, 2021–2026 · strength 1.26
  6. Kenneth H. Yu · 8 shared papers, 2017–2026 · strength 1.18
  7. William R. Jarnagin · 7 shared papers, 2021–2026 · strength 1.16
  8. Alice Chia-Chi Wei · 7 shared papers, 2021–2026 · strength 1.16
  9. Robert A. Wolff · 26 shared papers, 2011–2022 · strength 1.15
  10. Wungki Park · 7 shared papers, 2021–2026 · strength 1.11
  11. Jason B. Fleming · 26 shared papers, 2011–2021 · strength 1.07
  12. Jeffrey A. Drebin · 6 shared papers, 2021–2026 · strength 1.04
  13. Abraham Jing-Ching Wu · 7 shared papers, 2017–2025 · strength 1.03
  14. Gauri Rajani Varadhachary · 23 shared papers, 2011–2022 · strength 0.98
  15. Jeffrey E. Lee · 22 shared papers, 2011–2022 · strength 0.88
  16. Vinod P. Balachandran · 5 shared papers, 2021–2026 · strength 0.87
  17. Kevin C. Soares · 5 shared papers, 2021–2026 · strength 0.87
  18. Michael Ian D'Angelica · 5 shared papers, 2021–2026 · strength 0.87
  19. Eugene Jon Koay · 13 shared papers, 2014–2022 · strength 0.87
  20. Huamin Wang · 18 shared papers, 2012–2022 · strength 0.86
  21. Danny N. Khalil · 5 shared papers, 2021–2026 · strength 0.84
  22. William Adrian Hall · 6 shared papers, 2017–2024 · strength 0.78
  23. Milind M. Javle · 16 shared papers, 2011–2022 · strength 0.75
  24. Sunil Krishnan · 13 shared papers, 2011–2022 · strength 0.65
  25. T. Peter Kingham · 4 shared papers, 2021–2025 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.